Manufacturing Intelligence • Weekly Digest • March 25, 2026

TOP STORIES

Capacity UCB commits $2B to first U.S. biologics plant in Georgia—Bimzelx demand and tariff calculus drive the company's largest-ever capital investment

Georgia Governor Brian Kemp announced on March 24 that Belgium-based UCB will invest $2 billion to build a 460,000-square-foot biologics manufacturing facility at the Rowen Foundation's 2,000-acre science campus in Gwinnett County, approximately 35 miles northeast of Atlanta. The plant will be UCB's first pharmaceutical biologics manufacturing site in the United States and is expected to create 330+ permanent jobs (average salary exceeding $72,000) plus more than 1,000 construction roles. UCB projects approximately $5 billion in total economic impact, making it one of the largest life sciences investments in Georgia's history and the largest capital investment in Gwinnett County's history.

The facility will produce complex biologics 24/7, primarily immunology and neurology therapies, using AI, robotics, and automation. BioSpace reported that UCB CEO Jean-Christophe Tellier confirmed the investment will specifically support Bimzelx production—the IL-17A/IL-17F blocker whose U.S. sales surged nearly sixfold in 2025 to approximately €1.7 billion ($2 billion), making it the company's best-selling product. UCB evaluated up to 15 U.S. sites before selecting Rowen, drawn by the campus's scalability, proximity to major research universities (Georgia Tech, Emory), and availability of talent. HealthCare MEA noted that UCB's chief commercial officer described the investment as essential to owning a critical piece of the supply chain for major growth drivers.

Competitive implications: UCB joins a growing roster of European pharma companies establishing U.S. biologics manufacturing. Roche/Genentech doubled its Holly Springs, NC investment to $2 billion in January 2026; Samsung Biologics acquired its first U.S. site via the GSK Rockville deal; Novo Nordisk inherited Catalent's U.S. facilities (with mixed results). For CDMOs currently serving UCB's biologics production, the Georgia plant signals eventual insourcing of at least some contract manufacturing volume as UCB builds internal capacity. The Rowen campus itself gains credibility as a viable Southeast biotech hub with UCB as anchor tenant—a positioning advantage for attracting additional tenants.

Digital Pharmaceutical Technology's 2026 outlook: smart factories move from pilot to standard, complex molecules reshape production requirements

Pharmaceutical Technology published its comprehensive 2026 industry outlook in a series of expert interviews that map the forces reshaping drug manufacturing this year. The consensus from contributors including Hikma Pharmaceuticals' Manish Garg, Schneider Electric's Neil Smith, and Abzena's Campbell Bunce identifies three converging trends defining 2026 manufacturing strategy.

First: AI moves from experimentation to embedded operations. Garg describes an industry transition from scattered AI pilots to "smart factory" implementations incorporating IoT sensors, advanced robotics, and cloud computing infrastructure. The key barriers to full adoption remain data fragmentation, the lack of AI model interpretability for regulatory submission purposes, and a shortage of professionals with combined AI and pharmaceutical domain expertise. Smith predicts 2026 will reward manufacturers who deploy agentic AI to unlock value from legacy manufacturing constraints. Second: on-shoring is real and accelerating. Bunce describes a "genuine shift" with a major U.S. focus for drug substance manufacturing, while Neuland Laboratories' Saharsh Davuluri reports customers now requesting six months of API stock held in U.S. warehouses—a significant inventory buildup to de-risk against geopolitical disruption. Third: complex molecules are outgrowing conventional processes. Ecolab's Laine Mello notes that pipelines filled with high-concentration biologics and next-generation antibodies are pushing stability, aggregation, and purification to their limits, requiring continuous and intensified bioprocessing to become standard practice rather than innovation showcase.

CDMO DCAT Week 2026 opens with announcements signaling supply chain specificity over scale

Pharmaceutical Technology reported that three DCAT Week announcements reflect a sector investing in targeted capabilities rather than undifferentiated capacity growth. LGM Pharma expanded its U.S. manufacturing footprint with a $15 million investment across Texas and Colorado sites, adding commercial suppository manufacturing and oral solid dose capacity with a focus on orally disintegrating tablets—niche formats where domestic production is constrained. ICE Pharma announced a strategic repositioning beyond the traditional API supplier model, extending its ursodeoxycholic acid platform into finished dosage forms, nutraceutical gut/metabolic products, and functional excipients. ESTEVE CDMO is adding a 3,000-square-meter high-potency spray-drying unit at its Girona, Spain facility, with staged dryer deployments targeting poor solubility, stability, and scalability challenges in sponsor pipelines.

REGULATORY & COMPLIANCE

• Quality Manufacturing CRL wave update: The concentrated burst of manufacturing-driven FDA rejections from late February through mid-March (Ferring on Feb 27, Incyte on Mar 9, Hyloris on Mar 13) has focused DCAT Week discussions on CDMO quality risk management. PDA's CRL analysis continues to circulate as a reference, emphasizing that confidentiality constraints between CDMOs and clients create information asymmetries where sponsors may not learn about inspection problems at shared sites until a CRL arrives.
• Regulatory FDA CRL transparency policy continues to reshape industry behavior. Under the September 2025 policy, CRLs are published via openFDA promptly after issuance. BLA Regulatory noted that the FDA's AI tool "Elsa" may be used for CRL redactions, and legal challenges are expected given tensions with 21 CFR 314.430 confidentiality protections. For manufacturing-focused CRLs, the transparency means facility quality problems are now visible to the entire market—accelerating the shift toward dual-sourcing and sponsor-owned production.
• Regulatory Novo Nordisk regulatory status remains a background concern at DCAT Week. The company continues managing three concurrent FDA warning letters (Bloomington cGMP, Plainsboro PADE reporting, plus untitled letters for Ozempic/Wegovy marketing). No reinspection outcome at the Bloomington facility has been publicly announced, leaving affected clients Incyte, Scholar Rock, and Regeneron in varying stages of manufacturing transition.

CAPACITY & SUPPLY CHAIN

• Capacity UCB's Georgia investment adds to the expanding U.S. biomanufacturing geography. The Rowen campus positions metro Atlanta as a potential fourth major biomanufacturing cluster alongside Research Triangle (NC), greater Boston, and the Bay Area. UCB's existing U.S. headquarters have been in Smyrna, GA (near Atlanta) for over three decades, giving the company established local relationships and talent networks to draw from. The 2,000-acre Rowen campus has 1,900+ acres available for additional tenants.
• Capacity Eli Lilly's $3B China commitment (announced March 11) continues to generate discussion at DCAT Week in the context of dual-track geographic strategies. Lilly is now executing $50B U.S. + $3B China simultaneously for oral GLP-1 manufacturing. Orforglipron FDA approval remains expected in Q2 2026, with ~$550M in U.S. inventory pre-built.
• Deal AbbVie's $380M North Chicago API expansion (construction beginning spring 2026) and discussions with additional U.S. states for further investments join the UCB and Lilly announcements in maintaining the pace of reshoring investment through Q1 2026. AbbVie is now past $10B committed against its $100B decade-long target.
• CDMO DCAT Week networking dynamics this year are shaped by the convergence of tariff-driven reshoring demand, the CRL quality crisis, and CDMO M&A activity. Catalent (now Novo-owned) is hosting meetings at the Lotte New York Palace; Thermo Fisher is showcasing its Accelerator drug development platform; Pharmaron (Lilly's China CDMO partner) has a CMC delegation present. The make-versus-buy decision—always a DCAT Week subtext—is particularly charged this year as companies like UCB publicly signal their intent to insource biologics production.

WHAT TO WATCH NEXT

UCB facility timeline and Rowen campus development

UCB has not disclosed a specific operational target date for the Georgia facility, but analogous biologics greenfield projects (Genentech Holly Springs, Fujifilm Holly Springs) have 3–4 year construction-to-production timelines, suggesting late 2029 or 2030 for first commercial production. The more immediate signal will be whether the Rowen campus attracts additional life sciences tenants in 2026, which would validate the campus model and create the clustering dynamics (shared talent pools, supplier proximity) that drive regional manufacturing ecosystems. UCB's CDMO relationships during the interim construction period also bear watching: the company confirmed it has scaled up partnerships with U.S. contract manufacturers as a bridge, but has not named them publicly.

DCAT Week intelligence: which threads emerge from this year's meetings?

DCAT Week's value is primarily in the private business meetings rather than public programming, but several themes will surface in industry commentary over the coming weeks. Watch for signals on CDMO M&A movement (whether the Cambrex sale process has advanced, whether additional PE-backed CDMOs are formally marketing), reshoring contract win announcements (which CDMOs are capturing the most U.S.-bound production transfer work), and whether the manufacturing CRL crisis has changed how sponsors structure CDMO contracts (more dual-sourcing requirements, more explicit quality audit rights, shorter exclusivity periods). The LGM, ICE Pharma, and ESTEVE announcements suggest the CDMO sector is leaning into specialization—DCAT Week will reveal whether buyers are rewarding that positioning.

Smart factory adoption curve: from DCAT Week vision to operational reality

The PharmTech outlook describes a 2026 where AI, IoT, and digital twins are transitioning from pilots to standard manufacturing practice. UCB's Georgia plant, designed with AI and robotics from the ground up, represents the greenfield opportunity: building digital-native production facilities is far easier than retrofitting legacy plants. The harder question—and the one that matters more at scale—is how quickly existing facilities can be upgraded to Industry 4.0 standards. Garg's point about high upfront implementation costs and data silos as barriers to adoption suggests the transition will be uneven, creating a two-tier manufacturing landscape: digital-native new builds operating alongside legacy sites that may take years to modernize. For manufacturing strategy teams, the question is whether the investment in digital infrastructure at new sites creates competitive distance that legacy operations cannot close.